The challenge of therapy development in leukodystrophies

Bridging the gap between scientific progress and clinical translation

Leukodystrophies are a group of rare genetic disorders that affect the white matter of the brain and often lead to severe neurological impairment. While scientific advances have improved our understanding of these conditions, major challenges remain in developing therapies that can be effectively delivered, meaningfully evaluated and ultimately translated into clinical practice. POLARIS was created to help bridge this gap.

Three research objectives, one shared vision

Integrating gene therapy, pharmacological strategies and treatment evaluation

POLARIS is structured around three complementary research objectives. Together, they create a translational framework that connects scientific discovery with therapeutic impact.

WP1

Gene therapy strategies

Developing innovative genetic correction approaches and brain-targeting delivery platforms for selected leukodystrophies.

  • DC1 — Gene therapy development for selected leukodystrophies
  • DC2 — Gene therapy approaches in leukodystrophy models
  • DC3 — Whole-gene insertion as a platform technology
  • DC4 — Brain-targeting delivery platforms for gene therapies
WP2

Pharmacological therapy strategies

Building a complementary pipeline for small-molecule and biologic discovery, validation and optimisation.

  • DC5 — Fragment-based discovery for GPRC5B modulators
  • DC6 — GPRC5B drug discovery through AI-assisted virtual screening
  • DC7 — Nanobody discovery and optimisation for GPRC5B
  • DC8 — Patient-derived astrocyte models for therapy development
WP3

Treatment evaluation

Aligning therapeutic development with clinically meaningful, patient-relevant and affordable outcomes.

  • DC9 — Preclinical assessment in mouse models
  • DC10 — Zebrafish as a relevant model for therapy development
  • DC11 – DC12 — Quantitative MRI markers in ALD
  • DC13 — Quality of life as an outcome measure
  • DC14 — Body fluid biomarkers reflecting disease stage
  • DC15 — Regulatory and access pathways for leukodystrophy therapies